The December 2011 issue of Drug Safety Update from the MHRA includes an article discussing a safety review of the angiotensin receptor blockers (ARBs), recently completed by the European Medicines Agency.     

The CHMP reviewed a possible link between the use of ARBs and the occurrence of new cancers and concluded that the evidence does not support any increased risk of cancer in patients who use these medicines.  Please see the links below for details.